【摘要】 细胞周期蛋白依赖性激酶4/6(CDK4/6）抑制剂联合内分泌治疗已成为激素受体阳性（HR~+）、人类表皮生长因子受体-2阴性（HER2~-）乳腺癌患者的晚期一线及二线标准治疗方案。尽管CDK4/6抑制剂可实现有效的疾病控制，但对于晚期乳腺癌患者最终仍会因耐药出现疾病进展。目前CDK4/6抑制剂相关耐药机制尚不完全清楚，同时治疗失败后的最佳治疗策略仍是一个亟待解决的问题。本文就CDK4/6抑制剂的潜在耐药机制和后续治疗策略的最新研究进展做一综述。更多还原

【Abstract】 Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors plus endocrine therapy have been used as standard first-or second-line treatment for patients with hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer.Although CDK4/6 inhibitors provide excellent control in patients with hormone receptor-positive advanced breast cancer,due to drug resistance cancer progression will eventually occur as treatment proceeds.At present,the resistance mechanism of CDK4/6 inhibitors is not fully understood,and the optimal treatment strategy after failure of CDK4/6 inhibitors remains an urgent problem.This review summarized the potential resistance mechanism and subsequent treatment strategies of CDK4/6 inhibitors.更多还原